Metabolism Supplement Guide: What The Research Shows

Almost nobody buying a metabolism supplement wants a faster metabolic rate as such. They want one of four things: clothes that fit the way they used to, less of the mid-afternoon slump, an appetite that stops arguing at nine in the evening, or a scale that has stopped moving to start again. Those four are different problems with different evidence behind them, and a bottle that promises all four at once is promising across four literatures rather than one. Resting energy expenditure — the calories burned doing nothing — is largely set by lean tissue, age and thyroid function rather than by a dial a botanical turns. The most any ingredient here has been shown to do to it is the capsaicin result below, and that is about fifty-eight kilocalories a day.

Vinegar is the one name on a metabolism label whose human weight data survives pooling. The 2009 Japanese trial gave 155 adults with obesity 15 mL or 30 mL of vinegar a day — one or two tablespoons, carrying 750 or 1,500 mg of acetic acid — or a placebo drink, for twelve weeks. Body weight, fat mass and serum triglycerides all fell in the vinegar arms.

The numbers matter more than the direction. Across twelve weeks the difference against placebo was on the order of a kilogram to two, with the larger dose doing more — a real result from a properly randomised trial, and less than most people expect from twelve weeks of anything.

A 2025 systematic review and meta-analysis pooled the randomised trials in people with type 2 diabetes or overweight and found a standardised mean difference of about −0.39 on body weight, with the effect concentrated at the 30 mL end of the dose range. Concentrated at the top of the range is a useful phrase: it means the small doses in the pooled set were carrying very little of the result.

The counterweight is an eight-week trial of red wine vinegar that measured body fat directly. Glucose homeostasis improved and the metabolome shifted, and adiposity did not budge. Two trials, two endpoints, two answers — and the honest reading is that vinegar does something measurable to glucose handling and something much smaller and less reliable to fat mass.

Thirty millilitres is two tablespoons of vinegar a day, and that is where the pooled effect sits.

Green tea extract is the most commercially successful ingredient in this category and the one with the clearest verdict against it. The Cochrane review of green tea for weight loss and weight maintenance pooled eighteen randomised trials in overweight and obese adults and found a mean weight change small enough that the authors called it not clinically important.

Small but consistent is sometimes worth having. Here it was small and inconsistent: different populations, different catechin amounts, several trials funded by companies selling the extract, and a pooled figure under two kilograms whose confidence interval crosses into nothing. There is also a safety file, which is unusual in this category. A review of green tea extract and drug-induced liver injury documents hepatotoxicity linked to concentrated catechin extracts — not to drinking tea, which has an enormous safety record, but to the high-dose encapsulated form, and NCCIH's green tea page carries the same caution in consumer language. That distinction runs through the whole category: a plant with centuries of dietary use is being sold in a concentration nobody ever ate, and the safety record of the food does not transfer to the capsule.

Capsaicin is the ingredient that comes closest to doing what this category claims, which is why the number is worth printing. A meta-analysis of human capsaicin and capsiate studies found energy expenditure rose by roughly fifty-eight kilocalories a day, pooled across trials — and only in people whose BMI was above 25.

Fifty-eight kilocalories is a small apple. Sustained daily with nothing else changing, arithmetic says it adds up; in practice appetite adjusts, which is why the trials that measured weight rather than expenditure found much less than the expenditure figure predicts. The thermogenic effect is real, measurable and reproducible. It is also fifty-eight kilocalories, and the distance between that sentence and “fires up your metabolism” is the distance this whole category trades in.

Bitter melon appears on metabolism labels because of what it does to blood glucose, and that evidence is genuine if mixed. A 2019 meta-analysis found it lowered elevated glycaemia in type 2 diabetes, and one of the better-controlled trials used 2,000 mg a day for three months and reported improved insulin secretion.

The Cochrane review is the cold water. On bitter melon for type 2 diabetes specifically it found insufficient evidence to recommend it, on trials it judged small and at risk of bias. Two careful analyses of overlapping literature reaching different conclusions means the effect, if present, is not large enough to survive strict inclusion rules.

What matters for a metabolism label is that none of this is weight data. The endpoints were fasting glucose, HbA1c and insulin secretion, in people with diagnosed diabetes, at 2,000 mg a day for three months. Transferring that to a healthy adult who wants their jeans to fit involves an assumption no trial in the file supports.

Raspberry ketone reached the supplement aisle through a television segment rather than a trial, and the literature never caught up. A search of the indexed human literature returns cell work and animal work and nothing else, so there is no amount to compare a label against.

The best-designed animal study is the one worth knowing. Mice on a high-fat diet were given raspberry ketone, and it failed to reduce adiposity beyond what was explained by the animals simply eating less. In other words the compound suppressed intake, and the fat loss followed the reduced intake rather than any separate metabolic action.

A 2021 review of the compound surveys the pharmacology — the 3T3-L1 adipocyte work, the lipolysis signalling, the rodent models — and the human section is where it runs out of material. This is not an ingredient that failed. It is one that has never been tested in the species buying it.

Wild yam is the other end of the same problem. It is sold on the idea that diosgenin, the steroidal saponin it carries, becomes a hormone in the body — which it does in a laboratory, by a synthetic route developed in the 1940s, and not in a human being, which has no enzyme for that conversion. The one randomised, placebo-controlled, cross-over trial measured weight, blood pressure, cholesterol, triglycerides, HDL, FSH, glucose, oestradiol and progesterone. Nine endpoints, none of them moved.

Open enough metabolism labels and a second family of names appears: gotu kola, horse chestnut, butcher’s broom, grape seed, hawthorn, stone root, motherwort. These are not metabolic agents that happen to be less famous. They are the standard European venous stack, and their trials measure ankle circumference, leg volume and capillary filtration rate.

The 1996 horse chestnut trial compared 50 mg of escin twice daily — 100 mg a day, twelve weeks — against compression stockings and matched them on lower leg volume; the Cochrane review of horse chestnut seed extract covers leg pain, oedema and itching in chronic venous insufficiency. The gotu kola trial used 180 mg a day of total triterpenes and found the 30 mg schedule weaker, the butcher’s broom trial quotes a monograph dosage rather than a milligram figure, and pooled grape seed data on blood pressure has no single established amount.

The hawthorn dose-comparison trial is the most instructive of the set: 1,800 mg a day of the WS 1442 extract beat placebo on maximal workload, and 900 mg a day did not. Half the dose was not half the effect. It was no effect.

Two of the seven have essentially nothing. Stone root returns a single indexed paper, a cell-line screen, with no clinical literature at any dose. Motherwort has one published clinical study, using 1,200 mg a day of the oil extract over 28 days.

Pooled, the family gets more cautious than any single trial looks. The Cochrane review of phlebotonics, a 2025 review of venoactive agents and a 2024 review of herbal agents in vascular disease all describe the same shape: moderate-certainty evidence of a small effect on oedema, in people who have a diagnosed venous condition, using standardised solid oral extracts at stated amounts. Neither of those last two qualifiers survives the trip onto a label that lists seven of them together without amounts.

Every figure is an amount a published study used, not the contents of any product on sale.

A dietary supplement in the United States may describe support for a normal structure or function of the body. It may not claim to diagnose, treat, cure or prevent a disease, and it may not promise an outcome. The FDA's own questions and answers on dietary supplements sets out the boundary, and the NIH Office of Dietary Supplements consumer sheet covers the same ground for a reader rather than a lawyer.

That is why the language on these bottles is so uniform. “Supports healthy metabolism” is permitted and “melts fat away” is not; two phrases that look like variations in house style are a regulatory boundary. The consequence worth carrying to a shelf is that nothing in that framework requires a seller to prove a support claim before printing it. The claim must be truthful and the company must hold substantiation, but no agency reviews it first. A structure-function line is a statement about what a seller may write, not a finding about what is inside.

Efficacy here is a question of whether money was wasted. Safety is a different kind of question, and the record is larger than most buyers expect. A national study of emergency department visits estimated tens of thousands of United States visits a year linked to supplement adverse events, with slimming and energy products prominent among them.

A review of liver injury from herbal and dietary supplements documents the pattern: these products account for a rising share of drug-induced liver injury cases, with slimming and bodybuilding products over-represented.

A review of unapproved pharmaceutical ingredients should change how anyone shops. Hundreds of products carrying FDA warnings held undeclared prescription drugs — sibutramine in slimming products being the recurring example — and many stayed on sale afterwards. That risk attaches to the supply chain rather than to any plant.

Interactions are the mundane end of the same file. A systematic review of warfarin interactions catalogues how many common supplements alter anticoagulation, hawthorn has a measured interaction with digoxin, and escin's toxicology and hawthorn's safety review both matter to anyone already on a cardiac or blood-thinning medicine.